Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.

Executive Summary

Members of FDA's Anti-Infective Drugs Advisory Committee questioned the usefulness of approving antibiotics specifically for pathogen-resistant indications at a March 24 meeting held to discuss the safety and efficacy of Pharmacia & Upjohn's oxazolidinone antibiotic Zyvox (linezolid)

You may also be interested in...



Zyvox Phase IV Studies May Support Penicillin-Resistant Indications

Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.

Zyvox Phase IV Studies May Support Penicillin-Resistant Indications

Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.

Zyvox Comparison To Synercid In VRE Infections Recommended By FDA Cmte.

Pharmacia & Upjohn should conduct clinical trials comparing its oxazolidinone antibiotic Zyvox to Aventis' Synercid in the treatment of infections due to vancomycin-resistant enterococci, FDA's Anti-Infective Drugs Advisory Committee said March 24.

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel